The C5orf24 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human C5orf24 gene. This loss-of-function model, generated through CRISPR/Cas9-mediated gene disruption in HAP1 cells, comprises a heterogeneous pool of edited cells. The polyclonal format avoids clonal artifacts and provides a robust system for functional studies. It is designed to facilitate the elucidation of C5orf24??s biological role, which remains poorly understood.
HAP1 cells are a near-haploid human cell line with fibroblast-like, adherent morphology, derived from the male KBM-7 chronic myelogenous leukemia line. Their haploid genome simplifies genetic manipulation, as targeting a single allele often yields complete loss of function. This characteristic makes HAP1 cells an ideal platform for functional genomics, high-throughput genetic screens, and CRISPR-based knockout studies, offering a genetically tractable background for investigating uncharacterized genes like C5orf24.
C5orf24 is an uncharacterized protein-coding gene with no known molecular function, upstream regulators, downstream targets, or interacting partners. The encoded protein lacks recognizable functional domains, and its role in cellular pathways has not been established. Consequently, this knockout model is an essential tool for de novo discovery, enabling users to define the molecular interactors, signaling context, and biological significance of C5orf24 through systematic loss-of-function assays.
When employed in the HAP1 background, the C5orf24 knockout gains additional analytical power. The near-haploid state ensures that CRISPR/Cas9-mediated disruption of the single allele achieves efficient gene inactivation, minimizing confounding effects from residual wild-type alleles. Although C5orf24 is not directly implicated in disease, its chromosomal location at 5q31.1, a region frequently altered in cancers, suggests potential relevance to malignancy. These cells can therefore be used in cancer-oriented screens, such as synthetic lethality studies or genetic interaction mapping, to uncover functional ties to oncogenic processes.
Key applications include functional genomics, gene characterization, phenotypic screening, and genetic interaction mapping. Validation of knockout can be performed by western blotting and RT-qPCR, while transcriptomic consequences can be assessed via RNA-seq. The cells are amenable to cell proliferation, migration, and invasion assays, as well as drug sensitivity testing to evaluate therapeutic responses. They also support arrayed or pooled CRISPR screens for identifying genetic dependencies. For further details, please contact Ascent Research.
